Daniel Bensimhon, MD
Advanced Heart Failure and Transplant Cardiology · Greensboro, NCNPI 1245293505
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,384,583 of the $2,099,769 with a category attached, or 65.9%. It is spread thinly across 45 manufacturers, the largest accounting for just 15.2%. Among advanced heart failure and transplant cardiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,506 payments — averaging $1394.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sensible Medical Innovations Inc$318K
- Actelion Pharmaceuticals US, Inc.$296K
- Boehringer Ingelheim$259K
- Lilly USA, LLC$186K
- GE HealthCare$168K
- Bayer$147K
- plus $726K from 39 others
Across 16 payments — averaging $21,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sensible Medical Innovations Ltd$270K
- Actelion Pharmaceuticals, Ltd$43K
- Analog Devices Inc.$32K
Across 3 payments — averaging $13,754 each. An ownership or investment interest held by the physician or an immediate family member.
- Heartflow, Inc.$41K
What the payments were for
- Consulting fees$614,04129%
- Speaking & faculty fees$1,384,58366%
- Travel & lodging$67,1823%
- Food & beverage$30,5381%
- Education$3,4250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$427,373
- UPTRAVI$272,664
- OPSUMIT$230,354
- ReDS system$226,141
- Kerendia$146,001
- FUROSCIX$104,839
- ELIQUIS$98,828
- ENTRESTO$74,517
- FARXIGA$74,395
- Caption Guidance$65,321
- ZIO Patch$50,893
- WatchPat$38,370
- ZIO XT Patch$34,200
- WINREVAIR$33,220
- LOKELMA$13,834
- Attruby$6,175
- WatchPATONE$5,457
- Renal - PD$5,450
- Ozempic$4,500
- VYNDAQEL$3,225
How this compares
$2,099,769 in reported general payments places this provider in the 95th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 146 | $4,407,542 |
| OpsumitMacitentan | 110 | $1,416,496 |
| UptraviSelexipag | 56 | $1,296,615 |
| EntrestoSacubitril/Valsartan | 872 | $847,468 |
| EliquisApixaban | 613 | $454,054 |
| JardianceEmpagliflozin | 494 | $451,557 |
| FarxigaDapagliflozin Propanediol | 406 | $356,185 |
| AdempasRiociguat | 24 | $339,410 |
| WinrevairSotatercept-Csrk | 16 | $228,246 |
| XareltoRivaroxaban | 87 | $91,414 |
| Repatha SureclickEvolocumab | 66 | $68,857 |
| Ambrisentan | 22 | $48,233 |
| FuroscixFurosemide | 12 | $48,218 |
| CorlanorIvabradine Hcl | 52 | $39,883 |
| OzempicSemaglutide | 24 | $24,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $71,539 | $4,861,597759 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $295,731 | $2,713,111166 claims |
| NovartisEntresto | $88,723 | $847,468872 claims |
| Boehringer IngelheimJardiance | $259,276 | $451,557494 claims |
| AstraZenecaFarxiga, Brilinta | $93,448 | $374,083434 claims |
| BayerAdempas | $147,142 | $339,41024 claims |
| MerckWinrevair | $33,793 | $228,24616 claims |
| Johnson & JohnsonXarelto | $874 | $91,41487 claims |
| Scpharmaceuticals Inc.Furoscix | $105,373 | $48,21812 claims |
| AmgenCorlanor | $752 | $39,88352 claims |
| Novo NordiskOzempic | $4,520 | $24,39824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Greensboro
- Dalton McLeanGreensboro$22K
- Benjamin StonerGreensboro$3K
- Stephen GreeneDurham$582K
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Hassan AlhosainiWinston Salem$195K
- Vinay ThohanAsheville$164K
- Kishan ParikhRaleigh$158K
- Emil MissovGreenville$71K
- David IshizawarRaleigh$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.